What kind of company is Fluidigm?
Fluidigm Corporation is a public, American company engaged in the design, manufacture and sale of biological research equipment based on integrated fluidic circuit technology.
Where is Fluidigm located?
Fluidigm is headquartered in South San Francisco, CA and has 12 office locations across 10 countries.
How does Fluidigm BioMark work?
Technology. Our revolutionary integrated fluidic circuits (IFCs) empower life science research by automating molecular biology in nanoliter volumes. This means using less sample and reagent, and a single microfluidic device, to achieve the high-quality, consistent results your work depends on.
What is Fluidigm qPCR?
Fluidigm BioMark HD Services: The BioMark HD is an automated, high-performance PCR/qPCR system that uses microfluidics technology to process samples at nanoliter-scale volumes for gene expression, genotyping, sample identification, copy number variation analysis and digital PCR.
How many employees does Fluidigm have?
600+ Over 600 global employees driving to make a difference.
How big is Fluidigm?
Fluidigm’s current market capitalization is $288.4 m.
What is Fluidigm BioMark?
What does CyTOF stand for?
Cytometry by time of flight
Cytometry by time of flight, or CyTOF, is an application of mass cytometry used to quantify labeled targets on the surface and interior of single cells. CyTOF allows the quantification of multiple cellular components simultaneously using an ICP-MS detector.
Is Fluidigm a public company?
14, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced the closing of its previously announced underwritten public offering of 9,372,500 shares of its common stock.
What is the difference between qPCR and digital PCR?
Real-time PCR – also called quantitative polymerase chain reaction or qPCR – is one of the most powerful and sensitive gene analysis techniques and is used for a broad range of applications. Digital PCR is the next generation of PCR technology involving absolute quantitation of nucleic acid target sequences.